Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment
Shares of Bristol-Myers Squibb (NYSE: BMY ) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3. BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here